IP Library › Granted Patent US 8,999,327
Granted Patent B2
US 8,999,327 · App. 12/962,445 · Granted Apr 7, 2015

Antibodies against human CSF-1R and uses thereof

Inventors: Nikolaos Dimoudis (Wielenbach, DE); Georg Fertig (Penzberg, DE); Alexander Fidler (Penzberg, DE); Klaus Kaluza (Bad Heilbrunn, DE); Marlene Pickl (Penzberg, DE); Carola Ries (Penzberg, DE); Stefan Seeber (Penzberg, DE); Martin Lanzendoerfer (Tutzing, DE)
Assignee: Hoffman-La Roche Inc.
C07K16/2866C07K2317/56C07K2317/565C07K2317/567C07K2317/73C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,327
App. No.
12/962,445
Granted
Apr 7, 2015
Kind
B2
Abstract

The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Claims (12)

1. An isolated antibody binding to human CSF-1R, wherein

the heavy chain variable domain comprises SEQ ID NO:39 and the light chain variable domain comprises SEQ ID NO:40.

2. An isolated antibody binding to human CSF-1R, wherein

the heavy chain variable domain comprises a CDR3 region comprising SEQ ID NO: 33, a CDR2 region comprising SEQ ID NO: 34, and a CDR1 region comprising SEQ ID NO: 35, and the light chain variable domain comprises a CDR3 region comprising SEQ ID NO: 36, a CDR2 region comprising SEQ ID NO: 37, and a CDR1 region comprising SEQ ID NO: 38.

3. The antibody according to claim 1 or 2 , wherein said antibody is human IgG1 subclass.

4. A pharmaceutical composition comprising an antibody according to claim 1 .

5. A pharmaceutical composition comprising an antibody according to claim 2 .

6. A pharmaceutical composition comprising an antibody according to claim 3 .

7. The antibody according to claim 1 or 2 , wherein the antibody is a monoclonal antibody.

8. The antibody according to claim 1 or 2 , wherein the antibody is a chimeric, single chain, multispecific, or humanized antibody.

9. The antibody according to claim 1 or 2 , wherein the antibody is an antigen binding fragment.

10. The pharmaceutical composition according to claim 4 or 5 , wherein said antibody is formulated in a pharmaceutically acceptable carrier.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2021
From: GEORGES, GUY
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 057708/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2021
From: ROCHE DIAGNOSTICS GMBH
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 057708/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2021
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 057708/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2021
From: ROCHE DIAGNOSTICS GMBH
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 057708/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2011
From: DIMOUDIS, NIKOLAOS; FERTIG, GEORG; FIDLER, ALEXANDER; KALUZA, KLAUS; PICKL, MARLENE; RIES, CAROLA; SEEBER, STEFAN; MARTIN LANZENDOERFER (DECEASED), KERSTIN KRUEGER (LEGAL REPRESENTATIVE) OF
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 025930/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2011
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 025930/0058 →
Priority Claims (2)
EP 09015310 · Dec 10, 2009 · regional
EP 10173407 · Aug 19, 2010 · regional
Continuity (1)
Related Publication 20110165156A1 · Jul 7, 2011